Pharmacological management of chronic neuropathic pain - Consensus statement and guidelines from the canadian pain society

Pain Research and Management

Volumn 12, Issue 1, 2007, Pages 13-21

  Moulin, Dwight E ^a,t   Clark, A J ^b   Gilron, I ^c   Ware, M A ^d   Watson, C P N ^e   Sessle, B J ^f   Coderre, T ^d   Morley Forster, P K ^g   Stinson, J ^h   Boulanger, A ⁱ   Peng, P ^j   Finley, G A ^k   Taenzer, P ^l   Squire, P ^m   Dion, D ⁱ   Cholkan, A ⁿ   Gilani, A ^o   Gordon, A ^p   Henry, J ^o   Jovey, R ^p   Lynch, M ^q   Mailis Gagnon, A ^p   Panju, A ^r   Rollman, G B ^a   Velly, A ^s   more..

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g WESTERN UNIVERSITY   (Canada)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

ⁱ UNIVERSITÉ DE MONTRÉAL   (Canada)

^j UNIVERSITY HEALTH NETWORK   (Canada)

^k DALHOUSIE UNIVERSITY   (Canada)

^l UNIVERSITY OF CALGARY   (Canada)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁿ MOUNT SINAI HOSPITAL   (Canada)

^o MCMASTER UNIVERSITY   (Canada)

^p UNIVERSITY OF TORONTO   (Canada)

^q DALHOUSIE UNIVERSITY   (Canada)

^r MCMASTER UNIVERSITY   (Canada)

^s UNIVERSITY OF MINNESOTA   (United States)

^t LONDON REGIONAL CANCER PROGRAM   (Canada)

more..

Author keywords

Analgesic agents; Neuropathic pain; Randomized controlled trials

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; CANNABINOID; CITALOPRAM; CLONIDINE; DESIPRAMINE; DRONABINOL; DULOXETINE; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; LEVORPHANOL; LIDOCAINE; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; OXYCODONE; PAROXETINE; PLACEBO; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ANALGESIA; ATAXIA; BLURRED VISION; CANADA; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DISEASE MODEL; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; EUPHORIA; EVIDENCE BASED MEDICINE; HEART ARRHYTHMIA; HUMAN; MEDICAL SOCIETY; META ANALYSIS; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PERIPHERAL NERVOUS SYSTEM; PRACTICE GUIDELINE; PREVALENCE; RANDOMIZATION; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SYSTEMATIC REVIEW; URINE RETENTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 34248591500     PISSN: 12036765     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/730785     Document Type: Review

References (64)

1. Merskey H, Bogduk N, eds. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms, 2nd edn. Seattle: IASP Press, 1994:209-14.
2. Foley KM. Opioids and chronic neuropathic pain. N Engl J Med 2003;348:1279-81.
3. Low PA, Dotson RM. Symptomatic treatment of painful neuropathy. JAMA 1998;280:1863-4.
4. Jung BF, Ahrendt GM, Oaklander AL, Dworkin RH. Neuropathic pain following breast cancer surgery: Proposed classification and research update. Pain 2003;104:1-13.
5. Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: A practical guide for the clinician. CMAJ 2006;175:265-75.
6. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain. Arch Neurol 2003;60:1524-34.
7. MacPherson DW. Evidence-based medicine. Can Commun Dis Rep 1994;20:145-7.
8. Harden RN, Bruehl SP. Diagnostic criteria: The statistical derivation of the four criterion factors. In: Wilson P, Stanton-Hicks M, Harden RN, eds. CRPS: Current Diagnosis and Therapy, Progress in Pain Research and Management, Vol 32. Seattle: IASP Press, 2005:45-58.
9. Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:29-36.
10. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: Validation for use in clinic and postal research. J Pain 2005;6:149-58.
11. Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain 1997;73:123-39.
12. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217-27.
13. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 2000;55:915-20.
14. 2-delta proteins. CNS Drug Rev 2004;10:183-8.
15. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA 1998;280:1831-6.
16. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA 1998;280:1837-42.
17. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305.
18. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 2003;60:1274-83.
19. Sabatowski R, Galvez R, Cherry DA, et al; 1008-045 Study Group. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: Results of a randomised, placebo-controlled clinical trial. Pain 2004;109:26-35.
20. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebo-controlled trial. J Pain 2005;6:253-60.
21. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology 2004;63:2104-10.
22. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pan 2004:110:628-38.
23. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115:254-63.
24. Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK. Pregabalin in central neuropathic pain associated with spinal cord injury: A placebo-controlled trial. Neurology 2006;67:1792-800.
25. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-69.
26. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-18.
27. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56.
28. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:1411-20.
29. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Pain 2004;100:697-706. (Erratum in 2005;113:248).
30. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: A randomized, controlled trial. Neurology 2003;60:1284-9.
31. Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother 2002;36:236-40.
32. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: Results of an enriched enrollment study. Pain 1999;80:533-8.
33. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: Results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic, pain scale. Clin J Pain 2002;18:297-301.
34. Wasner G, Kleinert A, Binder A, Schattschneider J, Baron R. Postherpetic neuralgia: Topical lidocaine is effective in nociceptor-deprived skin. J Neurol 2005;252:677-86.
35. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 1995;37:246-53.
36. Abramowicz M. Tramadol - a new oral analgesic. Med Lett Drugs Ther 1995;37:59-62.
37. Smith AB, Ravikumar TS, Kamin M, Jordan D, Xiang J, Rosenthal N; CAPSS- 115 Study Group. Combination tramadol plus acetaminophen for postsurgical pain. Am J Surg 2004;187:521-7.
38. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: Systematic review and meta-analysis of randomized controlled trials. JAMA 2005;293:3043-52.
39. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: A randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41.
40. Raja SN, Haythornthwaite JA, Pappagoallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: A randomized placebo-controlled trial. Neurology 2002;59:1015-21.
41. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology 2003;60:927-34.
42. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-8.
43. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;329:253.
44. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-9.
45. Gorman A, Elliott K. Inturrisi C. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat brain and spinal cord. Neurosci Lett 1997;223:5-8.
46. Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK. Low dose methadone has an analgesic effect in neuropathic pain: A double-blind randomized controlled crossover trial. Palliat Med 2003;17:576-87.
47. Gagnon B, Almahrezi A, Schreier G. Methadone in the treatment of neuropathic pain. Pain Res Manag 2003;8:149-54.
48. Moulin DE, Palma D, Watling C, Schulz V. Methadone in the management of intractable neuropathic noncancer pain. Can J Neurol Sci 2005;32:340-3.
49. Lynch M. A review of the use of methadone for the treatment of chronic noncancer pain. Pain Res Manage 2005;10:133-44.
50. Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992;52:547-52.
51. Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990;42:135-44.
52. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-6.
53. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain 1999;83:389-400.
54. Sproule BA, Naranjo CA, Brenmer KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet 1997;33:454-71.
55. Lunardi G, Leandri M, Albano C, et al. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology 1997;48:1714-7.
56. Eisenberg E, Luria Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: A randomized, controlled study. Neurology 2001;57:505-9.
57. McCleane G. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: A randomised, double-blind, placebo controlled trial. Pain 1999;83:105-7.
58. Mao J, Chen LL. Systemic lidocaine for neuropathic pain relief. Pain 2000;87:7-17.
59. Galer BS, Harle J, Rowbotham MC. Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: A prospective study. J Pain Symptom Manage 1996;12:161-7.
60. Byas-Smith MG, Max MB, Muir J, Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design. Pain 1995;60:267-74.
61. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin or their combination for neuropathic pain. N Engl J Med 2005;352:1324-34.
62. Jovey RD, Ennis J, Gardner-Nix J, et al; Canadian Pain Society. Use of opioid analgesics for the treatment of chronic noncancer pain - A consensus statement and guidelines from the Canadian Pain Society, 2002. Pain Res Manag 2003;8(Suppl A):3A-14A.
63. Krames E. Implantable devices for pain control: Spinal cord stimulation and intrathecal therapies. Best Pract Res Clin Anesthesiol 2002;16:619-49.
64. Carter ML. Spinal cord stimulation in chronic pain: A review of the evidence. Anaesth Intensive Care 2004;32:11-21.